NCT04873869终止2 期
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 4
- 主要终点
- Percentage Change From Baseline in 28-day Seizure Frequency for Countable Motor Seizures During the 16-week Treatment Period
研究概览
简要总结
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 2 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 2 to 21 years of age, inclusive.
- •Have a diagnosis of SCN8A-DEE supported by both clinical and genetic findings
- •Have on average at least 1 countable motor seizure per week and not be seizure-free for more than 20 consecutive days
- •Being treated with at least 1 other antiseizure medication (ASM), but no more than 4 ASMs
- •Have failed to achieve seizure freedom with at least 2 ASMs
- •Must be using a nocturnal alerting system or practice consistent with standards of care at the time of screening and continue to use this for the duration of the study
- •Must have an adequate rescue medication regimen per the investigator's judgment in place at the time of screening and for the duration of the study
- •Have a body weight of at least 10 kg
- •The subject's parent/caregiver is able to accurately identify seizure types, especially countable motor seizures (defined as GTCS, tonic, atonic or FOS with noticeable motor component) and is able to complete seizure diary
排除标准
- •Have previously been enrolled in this study and received blinded treatment
- •Have participated in an interventional clinical trial < 30 days prior to screening
- •Have symptoms that would be more consistent with another epilepsy disorder such as Dravet syndrome (eg, fever-induced episodes of status epilepticus, frequent myoclonic seizures, worsening on sodium channel blockers, absence seizures with generalized spike-and-wave EEG as the sole seizure type)
- •Are currently receiving cannabinoids or medical marijuana except Epidiolex/Epidyolex, unless approved by the Sponsor
- •Are currently taking systemic steroids (excluding inhaled medication for asthma treatments and intranasal steroids for allergies). If subject has received these medications in the past, must be off these medications for at least 3 months prior to the screening visit and these drugs may not be initiated during the duration of the study. Intermittent steroids to treat nonepilepsy related diseases (such as allergies or dermatological conditions) are not exclusionary
- •Have a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect nervous system functioning
- •Have a clinically significant medical condition or chronic disease, that in the opinion of the investigator would preclude the subject from participating in and completing the study or that could confound interpretation of study outcome
- •Have clinically significant abnormal vital signs at the screening visit as determined by the investigator
- •Have one or more clinical laboratory test values outside the reference range, based on blood samples taken at the screening visit, that are of potential risk to the subject's safety as determined by the investigator
- •Have, at the screening visit, an electrocardiogram (ECG) finding of a corrected QT interval using Fridericia's formula (QTcF) > 450 msec or presence of any significant cardiac abnormality.
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive matching placebo for up to 18 weeks.
干预措施: Placebo (Drug)
NBI-921352
Experimental
In the first 6 weeks participants will receive increasing doses of NBI-921352 (Titration Period) based on weight, followed by 10 weeks of treatment at their final tolerated dose (Maintenance Period) and 2 weeks of treatment with decreasing doses (Taper Period).
干预措施: NBI-921352 (Drug)
结局指标
主要结局
Percentage Change From Baseline in 28-day Seizure Frequency for Countable Motor Seizures During the 16-week Treatment Period
时间窗: Planned time frame: Baseline to Week 16
次要结局
- Percentage of Participants With a Treatment Response(Planned time frame: Baseline to Week 16)
- Percentage Change From Baseline in 28-day Seizure Frequency for Countable Motor Seizures During the 10-week Maintenance Period(Planned time frame: Baseline, Week 6 to Week 16)
- Percentage of Participants With a ≥ 25%, ≥ 75%, or 100% Treatment Response During the 16-week Treatment Period(Planned time frame: Baseline to Week 16)
- Percentage of Participants With a ≥25%, ≥50%, ≥75%, or 100% Treatment Response During the 10-week Maintenance Period(Planned time frame: Baseline, Week 6 to Week 16)
- Clinical Global Impression of Change (CGIC) Score at Each Visit During the 16-week Treatment Period(Planned time frame: Up to Week 16)
- Parent/Caregiver Global Impression of Change (GIC) Score at Each Visit During the 16-week Treatment Period(Planned time frame: Up to Week 16)
- Change From Baseline in Clinical Global Impression of Severity (CGIS) Scores at Each Visit During the 16-week Treatment Period(Planned time frame: Baseline to Week 16)
- Change From Baseline in Parent/Caregiver Global Impression of Severity (GIS) Scores at Each Visit During the 16-week Treatment Period(Planned time frame: Baseline through Week 16)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
NBI-98854 Dose Titration Study for the Treatment of Tardive DyskinesiaTardive DyskinesiaNCT01733121Neurocrine Biosciences102
已完成
2 期
Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential TremorEssential TremorNCT04880616Neurocrine Biosciences31
已完成
2 期
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette SyndromeTourette SyndromeNCT02679079Neurocrine Biosciences98
已完成
2 期
Safety and Efficacy Study of NBI-98854 in Adults With Tourette SyndromeTourette SyndromeNCT02581865Neurocrine Biosciences124
撤回
2 期
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer PatientsLiver FibrosisHEPATITIS B CHRONICHepatocellular CarcinomaNCT02289300A2 Healthcare Taiwan Corporation